Corbus Pharmaceuticals Holdings, Inc.
Every calculator, already run for CRBP
Open the full toolkit →You have the numbers on CRBP. Get the argument.
A written report on which of these readings actually decide the outcome for Corbus Pharmaceuticals Holdings, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
9 analysts covering CRBPAnalyst Price Target Disagreement for Corbus Pharmaceuticals Holdings, Inc.
Wall Street's bull case implies +542% from the current price; the bear case implies +131%. A 411% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for CRBP
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
CRBP — frequently asked
Is CRBP a buy right now?
Wall Street's consensus rating on Corbus Pharmaceuticals Holdings, Inc. is Strong Buy across 9 analysts, with a mean price target of $33.81 (+352% vs. the current $7.48). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is CRBP's next earnings date?
Corbus Pharmaceuticals Holdings, Inc. is next scheduled to report earnings around Nov 16, 2026. A full CRBP research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Corbus Pharmaceuticals Holdings, Inc.?
Analysts covering Corbus Pharmaceuticals Holdings, Inc. (CRBP) range from a bear-case target of $17.25 to a bull-case high of $48.00, with a mean consensus target of $33.81 across 9 analysts. The spread of $30.75 (411% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Corbus Pharmaceuticals Holdings, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Corbus Pharmaceuticals Holdings, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CRBP research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Corbus Pharmaceuticals Holdings, Inc., in minutes. 3 free reports included with every account — no credit card required.